Progress of relapsed and refractory follicular lymphoma
10.3760/cma.j.issn.1009-9921.2018.04.005
- VernacularTitle: 复发难治性滤泡性淋巴瘤研究进展
- Author:
Danmin XU
1
;
Wei XU
Author Information
1. Department of Hematology, the First Affiliated Hospital with Nanjing Medical University, Jiangsu Province Hospital, Nanjing 210029, China
- Publication Type:Review
- Keywords:
Lymphoma, follicular;
Therapy;
Progress
- From:
Journal of Leukemia & Lymphoma
2018;27(4):209-211
- CountryChina
- Language:Chinese
-
Abstract:
Follicular lymphoma (FL) is a kind of indolent non-Hodgkin lymphoma deriving from follicle germinal center. Relapsed and refractory FL usually requires multiline treatments. With the great advance of novel drugs and a large number of clinical trials, the treatment model of FL has been changing continually. High dose therapy combined with hematopoietic stem cell transplant could provide preferable remissions for FL patients. Meanwhile, as more and more clinical trials have made great progress, novel drugs including inhibitors of PI3K, programmed death-1 (PD-1) or lenalidomide and antibody radionuclide conjugate have brought an increasing options for FL treatment.
